{
    "ticker": "ALXO",
    "name": "Alx Oncology Holdings Inc.",
    "description": "Alx Oncology Holdings Inc. is a clinical-stage immuno-oncology company dedicated to developing therapies that harness the immune system to fight cancer. Founded in 2015 and headquartered in Durham, North Carolina, Alx Oncology focuses on advancing its proprietary drug candidates through clinical development, with a particular emphasis on treating patients with advanced malignancies. The company's lead product candidate, evorpacept (ALX148), is a novel immune checkpoint inhibitor designed to enhance T cell activation and improve anti-tumor responses. Alx Oncology is committed to addressing significant unmet medical needs in oncology, and its innovative approach aims to provide new treatment options for patients facing challenging cancers. The company collaborates with leading research institutions and pharmaceutical partners to further its mission of transforming cancer care through the development of breakthrough therapies. With a strong pipeline and a dedicated team of professionals, Alx Oncology is poised to make a significant impact in the field of oncology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Durham, North Carolina, USA",
    "founded": "2015",
    "website": "https://www.alxoncology.com",
    "ceo": "Paul J. C. McGowan",
    "social_media": {
        "twitter": "https://twitter.com/AlxOncology",
        "linkedin": "https://www.linkedin.com/company/alx-oncology/"
    },
    "investor_relations": "https://investors.alxoncology.com",
    "key_executives": [
        {
            "name": "Paul J. C. McGowan",
            "position": "CEO"
        },
        {
            "name": "Hannah K. R. J. Smith",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Immuno-Oncology Therapies",
            "products": [
                "Evorpacept (ALX148)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Alx Oncology Holdings Inc. | Immuno-Oncology Drug Development",
        "meta_description": "Explore Alx Oncology Holdings Inc., a clinical-stage company focused on developing innovative immuno-oncology therapies to treat cancer. Learn about their lead product, evorpacept, and their commitment to transforming cancer care.",
        "keywords": [
            "Alx Oncology",
            "Immuno-Oncology",
            "Cancer Treatment",
            "Evorpacept",
            "Biotechnology",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Alx Oncology known for?",
            "answer": "Alx Oncology is known for developing innovative immuno-oncology therapies, particularly its lead product candidate, evorpacept."
        },
        {
            "question": "Who is the CEO of Alx Oncology?",
            "answer": "Paul J. C. McGowan is the CEO of Alx Oncology Holdings Inc."
        },
        {
            "question": "Where is Alx Oncology headquartered?",
            "answer": "Alx Oncology is headquartered in Durham, North Carolina, USA."
        },
        {
            "question": "What are Alx Oncology's main products?",
            "answer": "Alx Oncology's main product is evorpacept (ALX148), an immune checkpoint inhibitor."
        },
        {
            "question": "When was Alx Oncology founded?",
            "answer": "Alx Oncology was founded in 2015."
        }
    ],
    "competitors": [
        "BMY",
        "MRNA",
        "JNJ",
        "AMGN"
    ],
    "related_stocks": [
        "PFE",
        "GILD",
        "ABBV",
        "VRTX"
    ]
}